Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Intrinsic Value
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. [ Read More ]
The intrinsic value of one
BMRN
stock under the Base Case scenario is
66.57
USD.
Compared to the current market price of 83.07 USD,
Biomarin Pharmaceutical Inc
is
Overvalued by 20%.
Biomarin Pharmaceutical Inc's market capitalization is 15.7B USD.
BMRN stock price is 83.07 USD.
BMRN stock (66.57 USD) is 20% less than its price (83.07 USD).
BMRN stock price (83.07 USD) is 6% less than its Relative Value (88.74 USD). Open Relative Valuation
BMRN has upside potential of 35% compared to the average analyst price target.
Open Wall St Estimates
BMRN has positive Net Income for the last twelve months.
BMRN's ROIC (Return on Invested Capital) has increased in the last 3 years from -2% to 3%.
BMRN's Revenue has grown by 15% over the past 12 months.
BMRN has positive Free Cash Flow for the last twelve months.
BMRN's ROE (Return on Equity) for the past 12 months is very low and is equal to 4%.
BMRN's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
BMRN's Revenue has been growing by 9% per year for the last 3 years.
BMRN has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
BMRN's Revenue is forecast to grow at a rate of 15% per year over the next 3 years.
BMRN has positive Operating Income for the last twelve months.
BMRN's ROE (Return on Equity) has significantly decreased in the last 3 years from 21% to 4%.
BMRN has a very low three-year average ROIC (Return on Invested Capital): 0%. The company is not efficient at using invested capital to generate operating income.
BMRN has negative Net Debt. This means that the company has more cash and short-term investments (1B USD) than debt (593m USD).
BMRN's short-term assets (3B USD) exceed its short-term liabilties (1B USD).
BMRN has positive Gross Profit for the last twelve months.
BMRN's long-term assets (7B USD) exceed its long-term liabilties (2B USD).
BMRN earns more than enough operating income (158m USD) to safely cover interest payments on its debt (10m USD).
BMRN's D/E (Debt to Equity) is very low and is equal to 0.12.
BMRN's Altman Z-Score is very high and is equal to 6.2.
Valuation Backtest
Biomarin Pharmaceutical Inc
Run backtest to discover the historical profit from buying and selling
BMRN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Biomarin Pharmaceutical Inc
Balance Sheet Decomposition
Biomarin Pharmaceutical Inc
| Current Assets | 3B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 633.7m |
| Other Current Assets | 1.2B |
| Non-Current Assets | 3.9B |
| Long-Term Investments | 622.4m |
| PP&E | 1.1B |
| Intangibles | 490.9m |
| Other Non-Current Assets | 1.7B |
| Current Liabilities | 1.2B |
| Accounts Payable | 315.5m |
| Accrued Liabilities | 322.8m |
| Other Current Liabilities | 538.7m |
| Non-Current Liabilities | 713m |
| Long-Term Debt | 593.2m |
| Other Non-Current Liabilities | 119.9m |
Earnings Waterfall
Biomarin Pharmaceutical Inc
|
Revenue
|
2.4B
USD
|
|
Cost of Revenue
|
-514.9m
USD
|
|
Gross Profit
|
1.9B
USD
|
|
Operating Expenses
|
-1.7B
USD
|
|
Operating Income
|
158.1m
USD
|
|
Other Expenses
|
9.5m
USD
|
|
Net Income
|
167.6m
USD
|
Free Cash Flow Analysis
Biomarin Pharmaceutical Inc
BMRN Profitability Score
Profitability Due Diligence
Biomarin Pharmaceutical Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Biomarin Pharmaceutical Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
BMRN Solvency Score
Solvency Due Diligence
Biomarin Pharmaceutical Inc's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
Biomarin Pharmaceutical Inc's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BMRN Price Targets Summary
Biomarin Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for
BMRN
is 111.89 USD
with a low forecast of 80.8 USD and a high forecast of 147 USD.
Ownership
BMRN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BMRN Price
Biomarin Pharmaceutical Inc
| Average Annual Return | 4.34% |
| Standard Deviation of Annual Returns | 5.93% |
| Max Drawdown | -45% |
| Market Capitalization | 15.9B USD |
| Shares Outstanding | 189 775 008 |
| Percentage of Shares Shorted | 1.63% |
Company Profile
Biomarin Pharmaceutical Inc
Country
Industry
Market Cap
Dividend Yield
Description
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,045 full-time employees. The firm develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The firm's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The firm's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).
Contact
IPO
Employees
Officers
The intrinsic value of one
BMRN
stock under the Base Case scenario is
66.57
USD.
Compared to the current market price of 83.07 USD,
Biomarin Pharmaceutical Inc
is
Overvalued by 20%.
You don't have any saved screeners yet
